The treatment responses among different inhalation therapies for GOLD group E patients with chronic obstructive pulmonary disease.

ABSTRACT:

Background

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 revised the combined chronic obstructive pulmonary disease (COPD) assessment, merging groups C and D into group E, and revised the initial inhalation therapy recommendation. We aimed to evaluate the treatment responses among different inhalation therapies in GOLD group E patients stratified by the COPD assessment test (CAT) scores and forced expiratory volume in one-second percentage of predicted (FEV1%pred).

Methods

In this retrospective cohort study, we included patients with COPD registered in the Real World Research of Diagnosis and Treatment of COPD (RealDTC) study between January 2017 and June 2023. According to the GOLD 2023 report, we enrolled patients assigned to GOLD group E based on

SUBMITTER: Song Q 

PROVIDER: S-EPMC11842004 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature